文献
201. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery
aneurysms. Nat Genet 2008; 40: 35-42.
202. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-1058.
203. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-
347.
204. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of
acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639.
205. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health
professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young,
American Heart Association. Circulation 2004; 110: 2747-2771.
206. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical
course and coronary artery outcome. J Pediatr 2006; 149: 336-341.
207. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation
2006; 113: 2606-2612.
208. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki
disease: a prospective, randomised, open, blinded-endpoint trial. Lancet 2012; 379: 1613-1620.
209. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
N Engl J Med 2007; 356: 663-675.
210. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of nonresponsiveness to standard high-dose gamma-globulin therapy in patients with acute
Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131-137.
211. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr
2009; 168: 181-185.
212. Ogata S, Ogihara Y, Honda T, et al. Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics.
2012; 129: e17-23. [Epub ahead of print]
213. Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease: A
Retrospective Study. Circulation. 2011; 124: 2822-2828. [Epub ahead of print]
214. Uehara R, Yashiro M, Oki I, et al. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous
immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int 2007; 49: 427-430.
215. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin
and steroid pulse therapy. Pediatr Int 2001; 43: 211-217.
216. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;
93: 142-146.
217. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin
and steroid pulse therapy. J Cardiol 2009; 53: 15-19.
218. 三浦大，松岡恵，河野一樹，他．川崎病 発見後40年の軌跡と今後の課題. 治療 ガンマグロブリン無効例への対応 ステロイドパルス療法. 日本臨床
2008; 66: 338-342.
219. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005; 90:
1096-1097.
220. 日比野健一，芦田実華，岩島覚，他．川崎病治療に関する多施設共同研究. 日小誌 2008; 112: 1227-1232.
221. 鈴木啓之，荻野廣太郎，中村好一，他．川崎病急性期にステロイド投与を受けた症例の冠動脈障害発生の分析. 日小誌 2010; 114: 853-857.
222. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-810.
223. 佐地勉，中川雅生，小川俊一，他．急性期川崎病のIVIG不応例に対する生物学的製剤infliximab(レミケード)使用の調査報告－その安全性と有用性について
－ . 日小循誌 2009; 25: 68-69.
224. 佐地勉，小澤安文，竹内大二，他．最近の治療の進歩．川崎病におけるウリナスタチン療法．小児科 1999; 40: 1049-1054.
225. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001;
20: 635-637.
226. Suzuki H, Terai M, Hamada M, et al. Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin.
Pediatr Infect Dis J. 2011 May 16. [Epub ahead of print]
227. 城宏輔，清水博史，後藤和利．川崎病における血漿交換の効果．小児科診療 1984; 47: 354-362.
228. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr. 2004; 163: 263-264.
229. Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of
acetylcholine. J Am Coll Cardiol 1998; 31: 1074-1080.
230. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with
recent myocardial infarction. Circulation 2000; 101: 1102-1108.
231. 循環器病の診断と治療に関するガイドライン. 冠攣縮性狭心症の診断と治療に関するガイドライン. Circ J 2008; 72, Suppl. IV: 1195-1252.
232. Kimura E, Kishida H. Treatment of variant angina with drugs. A survery of 11 cardiology institutes in Japan. Circulation 1981; 63: 844-848.
233. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation
1996; 94: 266-271.
234. Tsuda E, Yasuda T, Naito H. Vasospastic angina in Kawasaki disease. J Cardiol 2008; 51: 65-69.
235. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
J Cardiovasc Pharmacol 2004; 44: 480-485.
236. Moriyama T, Karasawa A. Cardiovascular effects of benidipine and amlodipine in isolated tissue and anesthetized dogs. Biol Pharm Bull 1994;
17: 1468-1471.
237. Yao K, Ina Y, Nagashima K, et al. Antioxidant effects of calcium antagonists in rat brain homogenates. Biol Pharm Bull 2000; 23: 766-769.
238. Wang N, Minatoguchi S, Chen XH, et al. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein
kinase C dependent nitric oxide in rabbits. J Cardiovasc Pharmcol 2004; 43: 747-757.
239. Carter RW, Begaye M, Kanagy NL. Acute and chronic NOS inhibition enhances alpha(2)- adrenoreceptor stimulated Rho A and Rho kinese in rat
aorta. Am J Physiol Heart Circ Physiol 2002; 283: H1361-H1369.
240. Onouchi Z, Hamaoka K, Sakata K, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of
therapeutic regimens. Circ J 2005; 69: 265-272.
241. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. J Pediatr 2001;
138: 505-511.
242. Aizawa T, Ogasawara K, Nakamura F, et al. Effect of nicorandil on coronary apasm. Am J Cardiol 1989; 63: 75J-79J.
243. 河合忠一，榊原啓文，鏑木恒男．Nicorandil製剤（Perisalol®）の安静狭心症に対する効果並びに血中濃度との関連性についての検討. 薬理と治療 1985;
13: 3421-3433.
244. 循環器病の診断と治療に関するガイドライン. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン（2009年改訂版）.
http://www.j-circ.or.jp/guideline/pdf/JCS2004_kasanuki_h.pdf（ 2010年11月閲覧）．
245. 循環器病の診断と治療に関するガイドライン．川崎病心臓血管後遺症の診断と治療に関するガイドライン（2008年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawasy_h.pdf（2011年8月14日，2011年8月14日閲覧）．
246. 循環器病の診断と治療に関するガイドライン．心房細動治療（薬物）ガイドライン（2008年改訂版）．Circ J 2008; 72, Suppl. IV: 1581-1638.
247. ACCP Antithrombotic Therapy in Neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition) Chest 2008; 133: 887S-968S.
248. Yamada K, et al. The platelet functions in acute febrile mucocutaneous lymph node syndrome and a trial of prevention for thrombosis by antiplatelet
agent. Acta Haematol Jpn 1978; 41: 791-802.
249. Shirahata A, et al. Studies on blood coagulation and antithrombotic therapy in Kawasaki disease. Acta Paediatr Jpn 1983; 25: 104-115.
250. Masashi Taki, et al. Spontaneous platelet aggregation in Kawasaki disease using the particle counting method. Pediatrics International 2003; 45:
649-652.
251. 傳美和子，瀧正志，清水浩信，他．川崎病における可溶型P- セクレチンおよび血小板の膜表面に発現したP- セクレチンの臨床意義．聖マリアンナ医科大学
雑誌 1999; 27: 389-398.
252. Newburger J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee
on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation
2004; 110: 2747-2771.
253. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med
1999; 131: 429-501.
254. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-808.
255. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in
patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
256. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration With the Society of
Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.
J Am Coll Cardiol 2006; 48: el-el48.
257. Horstkotte D, Bergemann R, Althaus U, et al. German experience with low intensity anticoagulation (GELIA): protocol of a multi-center randomized,
prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993; 2: 411-419.
258. Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with
mechanical prosthetic heart valves. Circulation 1996; 94: 2107-2112.
259. Salem DN, O’Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 593S-629S.
260. Meschengieser SS, Fondevila CG, Frontroth J, et al. Lowintensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation
alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997; 113: 910-916.
261. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl
J Med 1993; 329: 524-529.
262. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and
morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study.
J Am Coll Cardiol 2000; 35: 739-746.
263. Rieder MJ, Reiner AP, GageBF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285
-2293.
264. Klein TE, Altman RB, Eriksson N, et al.; The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and
pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
265. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of
Atherosclerosis in Youth (PDAY) study. Circulation 2008; 117: 1216-1227.
266. Kuromori Y, Okada T, Iwata F, et al. Familial combined hyperlipidemia(FCHL) in children: the significance of early developmend of hyperapo B
lipoproteinemia, obesity and aging. J Atheroscler Thromb 2002; 9: 314-320.
267. Okada T, Murata M, Yamauchi K, et al. New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int 2002; 44:
596-601.
268. Al-Shaikh AM, et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial
hypercholesterolemia. Cardiol Young 2002; 12: 105-112.
269. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined
heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3332-3337.
270. Wiegman A, et al. Family history and cardiovascular risk in familial hypercholesterolemia: Data in more than 1000 children. Circulation 2003;
107: 1473-1478.
271. Wiegman A, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-370.
272. Arambepola C, Farmer AJ, Perera R, et al. Statin treatment for children and adolescents with heterozygous familial hypercholesterolemia:
A systemic review and meta-analysis. Atheroscler 2007; 195: 339-347.
273. Kavey REW, et al. Cardiovascular risk reduction in highrisk pediatric patients. Circulation 2006; 114: 2710-2738.
274. Weiss R, et al. Obesity and the metabolic syndrome in children and adolescents. New Eng J Med 2004; 350: 2362-2374.
275. Iwata F, et al. Screening for familial combined hyperlipidemia in children using lipid phenotypes.J Atheroscler Thromb 2003; 10: 299-303.
276. 原光彦，他．学童におけるメタボリックシンドロームの頻度と身体計測指標の関係について．肥満研究 2005; 11: 38-45.
277. Yoshinaga M, et al. Metabolic syndrome in overweight and obese Japanese children. Obes Res 2005; 13: 1135-1140.
278. 岡田知雄，他．小児肥満における内臓脂肪指標の変化と長鎖多価不飽和脂肪酸との関係について．肥満研究 2005; 11: 283-289.
279. Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery
calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27: 277-284.
280. Davis PH, Dawson JD, Riley WA, et al. Carotid intimalmedial thickness is related to cardiovascular risk factors measured from childhood through
middle age: The Muscatine Study. Circulation 2001; 104: 2815-2819.
281. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.
Jama 2003; 290: 2271-2276.
282. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-318.
283. Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review
for the US Preventive Services Task Force. Pediatrics 2007; 120: e189-214.
284. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.
Pediatrics 1992; 89: 495-501.
285. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 1996; 85: 1080-1082.
286. de Jongh S, Ose L, Szamosi T, Gagne C, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized,
double-blind, placebocontrolled trial with simvastatin. Circulation 2002; 106: 2231-2237.
287. Daniels SR, Greer FR, Committee on Nutrition: Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
288. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. Lancet 1992; 339: 1488.
289. McCrindle BW, Helden E, Cullen-Dean G, et al. A randomized crossover trial of combination pharmacologic therapy in children with familial
hyperlipidemia. Pediatr Res 2002; 51: 715-721.
290. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.
Pediatr Res 1996; 39: 867-871.
291. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian
Lovastatin in Children Study Group. Pediatrics 1996; 97: 619-628.
292. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe
hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 143: 74-80.
293. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.
Arterioscler Thromb Vasc Biol 2007; 27: 1803-1810.
294. de Jongh S, Lilien MR, op’t Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am
Coll Cardiol 2002; 40: 2117-2121.
295. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized
controlled trial. JAMA 2004; 292: 331-337.
296. http://www.pfizer.com/files/products/uspi_lipitor.pdf.
297. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004; 350:
1579-1582.
298. http://www.fda.gov/fdac/features/2001/301_preg.html
299. 住友直方, 岩本真理, 牛ノ濱大也, 他. 小児不整脈の診断・治療ガイドライン. 日小循誌 2010; 26(Supplement): 1-62.
300. 循環器病の診断と治療に関するガイドライン. 不整脈薬物治療に関するガイドライン(2009年改訂版).
http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
aneurysms. Nat Genet 2008; 40: 35-42.
202. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-1058.
203. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-
347.
204. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of
acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639.
205. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health
professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young,
American Heart Association. Circulation 2004; 110: 2747-2771.
206. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical
course and coronary artery outcome. J Pediatr 2006; 149: 336-341.
207. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation
2006; 113: 2606-2612.
208. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki
disease: a prospective, randomised, open, blinded-endpoint trial. Lancet 2012; 379: 1613-1620.
209. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
N Engl J Med 2007; 356: 663-675.
210. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of nonresponsiveness to standard high-dose gamma-globulin therapy in patients with acute
Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131-137.
211. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr
2009; 168: 181-185.
212. Ogata S, Ogihara Y, Honda T, et al. Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics.
2012; 129: e17-23. [Epub ahead of print]
213. Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease: A
Retrospective Study. Circulation. 2011; 124: 2822-2828. [Epub ahead of print]
214. Uehara R, Yashiro M, Oki I, et al. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous
immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int 2007; 49: 427-430.
215. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin
and steroid pulse therapy. Pediatr Int 2001; 43: 211-217.
216. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;
93: 142-146.
217. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin
and steroid pulse therapy. J Cardiol 2009; 53: 15-19.
218. 三浦大，松岡恵，河野一樹，他．川崎病 発見後40年の軌跡と今後の課題. 治療 ガンマグロブリン無効例への対応 ステロイドパルス療法. 日本臨床
2008; 66: 338-342.
219. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005; 90:
1096-1097.
220. 日比野健一，芦田実華，岩島覚，他．川崎病治療に関する多施設共同研究. 日小誌 2008; 112: 1227-1232.
221. 鈴木啓之，荻野廣太郎，中村好一，他．川崎病急性期にステロイド投与を受けた症例の冠動脈障害発生の分析. 日小誌 2010; 114: 853-857.
222. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-810.
223. 佐地勉，中川雅生，小川俊一，他．急性期川崎病のIVIG不応例に対する生物学的製剤infliximab(レミケード)使用の調査報告－その安全性と有用性について
－ . 日小循誌 2009; 25: 68-69.
224. 佐地勉，小澤安文，竹内大二，他．最近の治療の進歩．川崎病におけるウリナスタチン療法．小児科 1999; 40: 1049-1054.
225. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001;
20: 635-637.
226. Suzuki H, Terai M, Hamada M, et al. Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin.
Pediatr Infect Dis J. 2011 May 16. [Epub ahead of print]
227. 城宏輔，清水博史，後藤和利．川崎病における血漿交換の効果．小児科診療 1984; 47: 354-362.
228. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr. 2004; 163: 263-264.
229. Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of
acetylcholine. J Am Coll Cardiol 1998; 31: 1074-1080.
230. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with
recent myocardial infarction. Circulation 2000; 101: 1102-1108.
231. 循環器病の診断と治療に関するガイドライン. 冠攣縮性狭心症の診断と治療に関するガイドライン. Circ J 2008; 72, Suppl. IV: 1195-1252.
232. Kimura E, Kishida H. Treatment of variant angina with drugs. A survery of 11 cardiology institutes in Japan. Circulation 1981; 63: 844-848.
233. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation
1996; 94: 266-271.
234. Tsuda E, Yasuda T, Naito H. Vasospastic angina in Kawasaki disease. J Cardiol 2008; 51: 65-69.
235. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
J Cardiovasc Pharmacol 2004; 44: 480-485.
236. Moriyama T, Karasawa A. Cardiovascular effects of benidipine and amlodipine in isolated tissue and anesthetized dogs. Biol Pharm Bull 1994;
17: 1468-1471.
237. Yao K, Ina Y, Nagashima K, et al. Antioxidant effects of calcium antagonists in rat brain homogenates. Biol Pharm Bull 2000; 23: 766-769.
238. Wang N, Minatoguchi S, Chen XH, et al. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein
kinase C dependent nitric oxide in rabbits. J Cardiovasc Pharmcol 2004; 43: 747-757.
239. Carter RW, Begaye M, Kanagy NL. Acute and chronic NOS inhibition enhances alpha(2)- adrenoreceptor stimulated Rho A and Rho kinese in rat
aorta. Am J Physiol Heart Circ Physiol 2002; 283: H1361-H1369.
240. Onouchi Z, Hamaoka K, Sakata K, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of
therapeutic regimens. Circ J 2005; 69: 265-272.
241. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. J Pediatr 2001;
138: 505-511.
242. Aizawa T, Ogasawara K, Nakamura F, et al. Effect of nicorandil on coronary apasm. Am J Cardiol 1989; 63: 75J-79J.
243. 河合忠一，榊原啓文，鏑木恒男．Nicorandil製剤（Perisalol®）の安静狭心症に対する効果並びに血中濃度との関連性についての検討. 薬理と治療 1985;
13: 3421-3433.
244. 循環器病の診断と治療に関するガイドライン. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン（2009年改訂版）.
http://www.j-circ.or.jp/guideline/pdf/JCS2004_kasanuki_h.pdf（ 2010年11月閲覧）．
245. 循環器病の診断と治療に関するガイドライン．川崎病心臓血管後遺症の診断と治療に関するガイドライン（2008年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawasy_h.pdf（2011年8月14日，2011年8月14日閲覧）．
246. 循環器病の診断と治療に関するガイドライン．心房細動治療（薬物）ガイドライン（2008年改訂版）．Circ J 2008; 72, Suppl. IV: 1581-1638.
247. ACCP Antithrombotic Therapy in Neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition) Chest 2008; 133: 887S-968S.
248. Yamada K, et al. The platelet functions in acute febrile mucocutaneous lymph node syndrome and a trial of prevention for thrombosis by antiplatelet
agent. Acta Haematol Jpn 1978; 41: 791-802.
249. Shirahata A, et al. Studies on blood coagulation and antithrombotic therapy in Kawasaki disease. Acta Paediatr Jpn 1983; 25: 104-115.
250. Masashi Taki, et al. Spontaneous platelet aggregation in Kawasaki disease using the particle counting method. Pediatrics International 2003; 45:
649-652.
251. 傳美和子，瀧正志，清水浩信，他．川崎病における可溶型P- セクレチンおよび血小板の膜表面に発現したP- セクレチンの臨床意義．聖マリアンナ医科大学
雑誌 1999; 27: 389-398.
252. Newburger J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee
on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation
2004; 110: 2747-2771.
253. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med
1999; 131: 429-501.
254. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-808.
255. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in
patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
256. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration With the Society of
Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.
J Am Coll Cardiol 2006; 48: el-el48.
257. Horstkotte D, Bergemann R, Althaus U, et al. German experience with low intensity anticoagulation (GELIA): protocol of a multi-center randomized,
prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993; 2: 411-419.
258. Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with
mechanical prosthetic heart valves. Circulation 1996; 94: 2107-2112.
259. Salem DN, O’Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 593S-629S.
260. Meschengieser SS, Fondevila CG, Frontroth J, et al. Lowintensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation
alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997; 113: 910-916.
261. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl
J Med 1993; 329: 524-529.
262. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and
morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study.
J Am Coll Cardiol 2000; 35: 739-746.
263. Rieder MJ, Reiner AP, GageBF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285
-2293.
264. Klein TE, Altman RB, Eriksson N, et al.; The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and
pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
265. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of
Atherosclerosis in Youth (PDAY) study. Circulation 2008; 117: 1216-1227.
266. Kuromori Y, Okada T, Iwata F, et al. Familial combined hyperlipidemia(FCHL) in children: the significance of early developmend of hyperapo B
lipoproteinemia, obesity and aging. J Atheroscler Thromb 2002; 9: 314-320.
267. Okada T, Murata M, Yamauchi K, et al. New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int 2002; 44:
596-601.
268. Al-Shaikh AM, et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial
hypercholesterolemia. Cardiol Young 2002; 12: 105-112.
269. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined
heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3332-3337.
270. Wiegman A, et al. Family history and cardiovascular risk in familial hypercholesterolemia: Data in more than 1000 children. Circulation 2003;
107: 1473-1478.
271. Wiegman A, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-370.
272. Arambepola C, Farmer AJ, Perera R, et al. Statin treatment for children and adolescents with heterozygous familial hypercholesterolemia:
A systemic review and meta-analysis. Atheroscler 2007; 195: 339-347.
273. Kavey REW, et al. Cardiovascular risk reduction in highrisk pediatric patients. Circulation 2006; 114: 2710-2738.
274. Weiss R, et al. Obesity and the metabolic syndrome in children and adolescents. New Eng J Med 2004; 350: 2362-2374.
275. Iwata F, et al. Screening for familial combined hyperlipidemia in children using lipid phenotypes.J Atheroscler Thromb 2003; 10: 299-303.
276. 原光彦，他．学童におけるメタボリックシンドロームの頻度と身体計測指標の関係について．肥満研究 2005; 11: 38-45.
277. Yoshinaga M, et al. Metabolic syndrome in overweight and obese Japanese children. Obes Res 2005; 13: 1135-1140.
278. 岡田知雄，他．小児肥満における内臓脂肪指標の変化と長鎖多価不飽和脂肪酸との関係について．肥満研究 2005; 11: 283-289.
279. Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery
calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27: 277-284.
280. Davis PH, Dawson JD, Riley WA, et al. Carotid intimalmedial thickness is related to cardiovascular risk factors measured from childhood through
middle age: The Muscatine Study. Circulation 2001; 104: 2815-2819.
281. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.
Jama 2003; 290: 2271-2276.
282. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-318.
283. Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review
for the US Preventive Services Task Force. Pediatrics 2007; 120: e189-214.
284. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.
Pediatrics 1992; 89: 495-501.
285. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 1996; 85: 1080-1082.
286. de Jongh S, Ose L, Szamosi T, Gagne C, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized,
double-blind, placebocontrolled trial with simvastatin. Circulation 2002; 106: 2231-2237.
287. Daniels SR, Greer FR, Committee on Nutrition: Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
288. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. Lancet 1992; 339: 1488.
289. McCrindle BW, Helden E, Cullen-Dean G, et al. A randomized crossover trial of combination pharmacologic therapy in children with familial
hyperlipidemia. Pediatr Res 2002; 51: 715-721.
290. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.
Pediatr Res 1996; 39: 867-871.
291. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian
Lovastatin in Children Study Group. Pediatrics 1996; 97: 619-628.
292. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe
hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 143: 74-80.
293. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.
Arterioscler Thromb Vasc Biol 2007; 27: 1803-1810.
294. de Jongh S, Lilien MR, op’t Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am
Coll Cardiol 2002; 40: 2117-2121.
295. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized
controlled trial. JAMA 2004; 292: 331-337.
296. http://www.pfizer.com/files/products/uspi_lipitor.pdf.
297. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004; 350:
1579-1582.
298. http://www.fda.gov/fdac/features/2001/301_preg.html
299. 住友直方, 岩本真理, 牛ノ濱大也, 他. 小児不整脈の診断・治療ガイドライン. 日小循誌 2010; 26(Supplement): 1-62.
300. 循環器病の診断と治療に関するガイドライン. 不整脈薬物治療に関するガイドライン(2009年改訂版).
http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
小児期心疾患における薬物療法ガイドライン
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）